Dr. Trevor Snow

Dr. Trevor Snow is a senior procurement specialist focused on advancing biotechnology research and development through strategic federal acquisitions. Though his official title and agency are not publicly designated, his procurement activities center on high-complexity R&D initiatives requiring deep scientific and regulatory expertise. He manages the full lifecycle of contracts for innovative biotech solutions, including preclinical studies, diagnostic platform development, and translational research services, ensuring alignment with federal science and health objectives. His role is critical in translating national research priorities into executable contractual frameworks that support cutting-edge innovation. Dr. Snow’s contractor relationships are characterized by engagement with specialized biotechnology firms possessing advanced laboratory capabilities, GMP compliance, and expertise in molecular biology and bioinformatics. He consistently partners with organizations capable of delivering proprietary research outputs under strict intellectual property and data integrity protocols. While no single contractor dominates his portfolio, his selections reflect a preference for firms with proven track records in federally funded biotech programs, often involving collaborative research agreements and cost-reimbursement contract types. Dr. Snow’s contracting approach reflects a strong emphasis on open competition, with 100% of his acquisitions classified as “No Set-Aside.” This indicates a focus on technical merit and capability over socioeconomic preferences, prioritizing the most qualified performers regardless of business size or certification status. His pattern suggests a mission-driven allocation strategy where scientific rigor and innovation capacity outweigh socioeconomic targeting criteria. His primary NAICS classification, 541714—Research and Development in Biotechnology—defines his entire procurement portfolio. He procures services spanning gene sequencing, protein engineering, biomarker discovery, and biopharmaceutical process development. His domain expertise lies at the intersection of regulatory science, clinical translation, and life sciences innovation, making him a key gatekeeper for federally supported biotech advancement.